Erratum: Serum protein profilling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid alpha in renal cancer patients (Laboratory Investigation (2004) 84 845-856.) doi:10.1038/labinvest.3700097));Serum protein profiling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid alpha in renal cancer patients

Laboratory Investigation

Volumn 84, Issue 7, 2004, Pages 845-856

  Tolson, Jonathan ^a   Bogumil, Ralf ^b   Brunst, Elke ^c   Beck, Hermann ^c   Elsner, Raimund ^d   Humeny, Andreas ^e   Kratzin, Hartmut ^f   Deeg, Martin ^a   Kuczyk, Markus ^a   Mueller, Gerhard A ^c   Mueller, Claudia A ^a   Flad, Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Ciphergen Biosystems GmbH   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Evangelical Hospital   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Biomarker; Haptoglobin; ProteinChip; Renal cell carcinoma; SELDI; Serum; Serum amyloid alpha

Indexed keywords

AMINO ACID; AMYLOID ALPHA PROTEIN; AMYLOID PROTEIN; ARGININE; BIOLOGICAL MARKER; HAPTOGLOBIN; SERINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; SEROLOGY;

EID: 3042543533     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700140     Document Type: Erratum

References (32)

1. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-580.
2. Wright Jr GL. SELDI Proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-563.
3. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868-1875.
4. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostatespecific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-6033.
5. Li J, Zhang Z, Rosenweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
6. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
7. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
8. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
9. Srinivas PR, Srivastava S, Hanash S, et al. Proteomics in early detection of cancer. Clin Chem 2001;47:1901-1911.
10. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001;88:818-824.
11. Godley PA, Ataga KI. Renal cell carcinoma. Curr Opin Oncol 2000;12:260-264.
12. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 2000;27:160-176.
13. Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta 2001;313:231-239.
14. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-69.
15. O'Hanlon DM, Lynch J, Cormican M, et al. The acute phase response in breast carcinoma. Anticancer Res 2002;22:1289-1293.
16. Glojnaric I, Casl MT, Simic D, et al. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab 2001;39:129-133.
17. Bíró L, Domján Gy, Falus A, et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998;28:679-686.
18. Blay J-Y, Rossi J-F, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal cell carcinoma. Int J Cancer 1997;72:424-430.
19. Raynes JG, Eagling S, McAdam KP. Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 1991;83:488-491.
20. Kluve-Beckerman B, Dwulet FE, Benson MD. Human serum amyloid A: three hepatic mRNAs and the corresponding proteins in one person. J Clin Invest 1988;82:1670-1675.
21. Raynes JG, McAdam KP. Serum amyloid A isoforms in inflammation. Scand J Immunol 1991;33:657-666.
22. Patel H, Bramall J, Waters H, et al. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 1996;318:1041-1049.
23. Baba S, Takahashi T, Kasama T, et al. A novel polymorphism of human serum amyloid A protein, SAA1γ, is characterized by alanines at both residues 52 and 57. Arch Biochem Biophys 1993;303:361-366.
24. Strachan AF, Brandt WF, Woo P, et al. Human serum amyloid A protein: the assignment of six major isoforms to three published gene sequences and evidence for two gene loci. J Biol Chem 1989;264:18368-18373.
25. Kiernan UA, Tubbs KA, Nedelkov D, et al. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 2003;537:166-170.
26. Urieli-Shoval S, Cohen P, Eisenberg S, et al. Widespread expression of serum amyloid A in histologically normal tissues: predominant localization to the epithelium. J Histochem Cytochem 1998;46:1377-1384.
27. Huber W, Boer JM, von Heydebreck A, et al. Transcription profiling of renal cell carcinoma. Verh Dtsch Ges Pathol 2002;86:153-164.
28. Ducret A, Foyn Bruun C, Bures EJ, et al. Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis 1996;17:866-876.
29. Turnell W, Sarra R, Glover ID, et al. Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. Mol Biol Med 1986;3:387-407.
30. Stix B, Kähne T, Sletten K, et al. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 2001;159:561-570.
31. Wassell J. Haptoglobin: function and polymorphism. Clin Lab 2000;46:547-552.
32. Rai AJ, Zhang Z, Rosenzweig BS, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126:1518-1526.